Stroke: 'Time is brain' after stroke, regardless of age and severity

Nature Reviews Neurology

Volumn 10, Issue 12, 2014, Pages 675-676

  Audebert, Heinrich J ^a   Sobesky, Jan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

AGE DISTRIBUTION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CENTRALIZATION; CEREBROVASCULAR ACCIDENT; DISEASE SEVERITY; DRUG EFFICACY; EARLY INTERVENTION; ELDERLY CARE; FIBRINOLYTIC THERAPY; GLASGOW OUTCOME SCALE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; LENGTH OF STAY; META ANALYSIS (TOPIC); MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; SECONDARY PREVENTION; SHORT SURVEY; STROKE PATIENT; SURVIVAL RATE; TELEMEDICINE; TRANSIENT ISCHEMIC ATTACK; UNITED KINGDOM; AGE; BRAIN; DRUG EFFECTS; HOSPITAL MANAGEMENT; PATHOPHYSIOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; STROKE; TIME TO TREATMENT;

AGE FACTORS; BRAIN; CENTRALIZED HOSPITAL SERVICES; ENGLAND; HUMANS; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOLYTIC THERAPY; TIME-TO-TREATMENT;

EID: 84927175318     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.194     Document Type: Short Survey

References (10)

1. [No authors listed] Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333, 1581-1587 (1995).
2. Lees, K. R. et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375, 1695-1703 (2010).
3. Fonarow, G. C. et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation 123, 750-758 (2011).
4. Bray, B. D. et al. Stroke thrombolysis in England: an age stratified analysis of practice and outcome. Age Ageing 42, 240-245 (2013).
5. Emberson, J. et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet http://dx.doi.org/10.1016/S0140-6736(14)60584-5.
6. Sandercock, P. et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet 379, 2352-2363 (2012).
7. Bray, B. D. et al. Bigger, faster? Associations between hospital thrombolysis volume and speed of thrombolysis administration in acute ischemic stroke. Stroke 44, 3129-3135 (2013).
8. Bray, B. D. et al. Associations between the organisation of stroke services, process of care, and mortality in England: prospective cohort study. BMJ 346, f2827 (2013).
9. Morris, S. et al. Impact of centralising acute stroke services in English metropolitan areas on mortality and length of hospital stay: difference-in-differences analysis. BMJ 349, g4757 (2014).
10. Muller-Barna, P. et al. TeleStroke units serving as a model of care in rural areas: 10-year experience of the TeleMedical Project for integrative stroke care. Stroke 45, 2739-2744 (2014).